Skip to main content

Branded

  • Reports: Humira to become top-selling drug this year

    NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

  • Amgen to acquire Kai for $315 million

    THOUSAND OAKS, Calif. — Biotech manufacturer Amgen will acquire the private South San Francisco, Calif.-based drug developer Kai Pharmaceuticals for $315 million, the companies said Tuesday.

    The deal includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Amgen has provided a loan to fund phase-3 clinical studies of the drug and will acquire rights to it worldwide, except for Japan.

  • Lawsuit challenging ESI-Medco merger begins

    NEW YORK — Pharmacies hoping to block the merger between pharmacy benefit managers Express Scripts and Medco Health Solutions got their day in court Tuesday, according to published reports.

    Bloomberg reported that a hearing in the U.S. District Court for the Western District of Pennsylvania began in Pittsburgh, with the National Association of Chain Drug Stores, the National Community Pharmacists Association and several independent pharmacies hoping to stop the $29.1 billion merger, which the Federal Trade Commission approved last week.

  • FDA approves labeling change for Novo Nordisk diabetes drug

    PRINCETON, N.J. — The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

  • Pfizer brings Lipitor marketing campaign to Walgreens Chicago flagship store

    CHICAGO — Drug maker Pfizer is taking a marketing campaign for one of its drugs to Walgreens' Chicago flagship store to raise awareness about high cholesterol and healthy eating, the company said Monday.

  • FDA advisory committee recommends approval for Astellas overactive bladder drug

    DEERFIELD, Ill. — A panel of Food and Drug Administration experts has recommended approval for a drug made by Astellas Pharma for overactive bladder.

    The drug maker announced that the FDA Reproductive Health Drugs Advisory Committee voted 7-4 with one abstention that its assessment of the risks and benefits of the drug YM178 (mirabegron) supported the drug's approval.

    The FDA is not required to follow the recommendations of advisory committees, but usually does. The agency is expected to decide whether or not to approve the drug by June 29.

  • Par launches generic version of Provigil

    WOODCLIFF LAKE, N.J. — Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

    Par announced the launch of a generic version of Provigil (modafinil), used to treat such sleep disorders as narcolepsy and work shift sleep disorder.

  • Study finds quadrivalent FluMist vaccine more effective than traditional inoculations

    ST. LOUIS — An intranasal vaccine that includes four weakened strains of influenza could do a better job in protecting children from the flu than current vaccines, research released Tuesday by St. Louis University found.

X
This ad will auto-close in 10 seconds